Do not reproduce without permission
Liraglutide (50, 100, and 200 g/kg/12 h) treatment protected against nonalcoholic fatty liver disease by inhibition of ER stress-associated apoptosis in HFD-fed rats [28]
Importantly, unlike some weight loss medications associated with cardiovascular risks, GLP-1 agonists exhibit neutral or even beneficial cardiovascular outcomes, providing reassurance regarding their long-term safety
They may adjust your dosage or provide additional recommendations to help manage your symptoms effectively
Still, if you notice any warning signs or discomfort after you start using the medication, it is highly recommended to contact a specialist
Anyone with an open abdominal hernia should not receive a fat reduction in that area